

JOSH GREEN, M.D.  
GOVERNOR  
KE KIA'ĀINA



GOV. MSG. NO. 1207

EXECUTIVE CHAMBERS  
KE KE'ENA O KE KIA'ĀINA

May 29, 2025

The Honorable Ronald D. Kouchi  
President of the Senate,  
and Members of the Senate  
Thirty-Third State Legislature  
State Capitol, Room 409  
Honolulu, Hawai'i 96813

The Honorable Nadine Nakamura  
Speaker, and Members of the  
House of Representatives  
Thirty-Third State Legislature  
State Capitol, Room 431  
Honolulu, Hawai'i 96813

Aloha President Kouchi, Speaker Nakamura, and Members of the Legislature:

This is to inform you that on May 29, 2025, the following bill was signed into law:

S.B. NO. 1452, S.D. 1,  
H.D. 2, C.D. 1

RELATING TO THE UNIFORM CONTROLLED  
SUBSTANCE ACT.  
**ACT 107**

Mahalo,

A handwritten signature in black ink that reads "Josh Green M.D." in a cursive style.

Josh Green, M.D.  
Governor, State of Hawai'i

---

---

# A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.

**BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:**

1           SECTION 1. Section 329-14, Hawaii Revised Statutes, is  
2 amended as follows:

3           1. By amending subsection (b) to read:

4           "(b) [Any] Opiates. Unless specifically excepted or  
5 unless listed in another schedule, any of the following opiates,  
6 including their isomers, esters, ethers, salts, and salts of  
7 isomers, esters, and ethers, [~~unless specifically excepted,~~]  
8 whenever the existence of these isomers, esters, ethers, and  
9 salts is possible within the specific chemical designation:

- 10           (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-  
11 phenethyl)-4-piperidinyl]-N-phenylacetamide);  
12           (2) Acetylmethadol;  
13           (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
14 phenylacetamide), its optical, positional, and  
15 geometric isomers, salts, and salts of isomers;  
16           (4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-  
17 phenylacrylamide] (Other name: acryloylfentanyl);



- 1 (5) AH-7921 (3,4-dichloro-N-[(1-  
2 dimethylamino)cyclohexylmethyl]benzamide);
- 3 (6) Allylprodine;
- 4 (7) Alphacetylmethadol (except levo-alphacetylmethadol,  
5 levomethadyl acetate, or LAAM);
- 6 (8) Alphameprodine;
- 7 (9) Alphamethadol;
- 8 (10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-  
9 phenethylpiperidin-4-yl)-N-phenylbutanamide);
- 10 ~~[(10)]~~ (11) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-  
11 phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-  
12 2-phenylethyl)-4-(N-propanilido)piperidine);
- 13 ~~[(11)]~~ (12) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-  
14 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 15 ~~[(12)]~~ (13) Benzethidine;
- 16 ~~[(13)]~~ (14) Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N-  
17 phenylpropanamide); its optical isomers, salts, and  
18 salts of isomers;
- 19 ~~[(14)]~~ (15) Betacetylmethadol;
- 20 ~~[(15)]~~ (16) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-  
21 phenethyl)-4-piperidinyl]-N-phenylpropanamide);





- 1        [~~+24~~] (27) Clonitazene;
- 2        (28) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-
- 3        N-phenylbut-2-enamide);
- 4        (29) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
- 5        phenylcyclopentanecarboxamide);
- 6        [~~+25~~] (30) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-
- 7        yl)-N-phenylcyclopropanecarboxamide);
- 8        [~~+26~~] (31) Dextromoramide;
- 9        [~~+27~~] (32) Diampromide;
- 10       [~~+28~~] (33) Diethylthiambutene;
- 11       [~~+29~~] (34) Difenoxyin;
- 12       [~~+30~~] (35) Dimenoxadol;
- 13       [~~+31~~] (36) Dimepheptanol;
- 14       (37) 2',5'-dimethoxyfentanyl (N-(1-(2,5-
- 15       dimethoxyphenethyl)piperidin-4-yl)-N-
- 16       phenylpropionamide);
- 17       [~~+32~~] (38) Dimethylthiambutene;
- 18       [~~+33~~] (39) Dioxaphetyl butyrate;
- 19       [~~+34~~] (40) Dipipanone;
- 20       [~~+35~~] (41) Ethylmethylthiambutene;



- 1        (42)    Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-  
2        1-yl)-N,N-diethylethan-1-amine) (Other name:  
3        etazene);
- 4        [~~+36~~] (43)    Etonitazene;
- 5        [~~+37~~] (44)    Etoxeridine;
- 6        [~~+38~~] (45)    Fentanyl carbamate (ethyl (1-phenethylpiperidin-  
7        4-yl) (phenyl) carbamate);
- 8        (46)    Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-  
9        nitro-1H-benzimidazol-1-yl)ethan-1-amine);
- 10       [~~+39~~] (47)    4-fluoroisobutyryl fentanyl [N-(4-fluorophenyl)-  
11       N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other  
12       name: para-fluoroisobutyryl fentanyl);
- 13       [~~+40~~] (48)    2'-fluoro ortho-fluorofentanyl (N-(1-(2-  
14       fluorophenethyl)piperidin-4-yl)-N-(2-  
15       fluorophenyl)propionamide) (Other name: 2'-fluoro 2-  
16       fluorofentanyl);
- 17       [~~+41~~] (49)    Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-  
18       N-phenylfuran-2-carboxamide);
- 19       (50)    3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
20       phenylfuran-3-carboxamide);
- 21       [~~+42~~] (51)    Furethidine;



- 1        [~~43~~] (52) Hydroxypethidine;
- 2        (53) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
- 3        phenylisobutyramide);
- 4        (54) Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-
- 5        5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
- 6        (55) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-
- 7        4-yl)-N-phenylbutanamide);
- 8        [~~44~~] (56) Ketobemidone;
- 9        [~~45~~] (57) Levomoramide;
- 10       [~~46~~] (58) Levophenacymorphan;
- 11       (59) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-
- 12       phenethylpiperidin-4-yl)propionamide);
- 13       (60) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-
- 14       (1-phenethylpiperidin-4-yl)isobutyramide);
- 15       [~~47~~] (61) Methoxyacetyl fentanyl (2-methoxy-N-(1-
- 16       phenethylpiperidin-4-yl)-N-phenylacetamide);
- 17       (62) 2-methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-
- 18       yl)piperazin-1-yl)butan-1-one);
- 19       [~~48~~] (63) 4'-methyl acetyl fentanyl (N-(1-(4-
- 20       methylphenethyl)piperidin-4-yl)-N-phenylacetamide);







- 1        (84) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-  
2        (1-phenethylpiperidin-4-yl)isobutyramide);
- 3        [~~+64~~] (85) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-  
4        N-(1-phenethylpiperidin-4-yl)butyramide);
- 5        [~~+65~~] (86) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-  
6        phenethyl)-4-piperidinyl]propanamide [∓]);
- 7        [~~+66~~] (87) Para-fluoro furanyl fentanyl (N-(4-  
8        fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-  
9        carboxamide);
- 10       (88) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-  
11       (1-phenethylpiperidin-4-yl)butyramide);
- 12       (89) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-  
13       (1-phenethylpiperidin-4-yl)furan-2-carboxamide);
- 14       (90) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-  
15       (1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
- 16       [~~+67~~] (91) Para-methylfentanyl (N-(4-methylphenyl)-N-(1-  
17       phenethylpiperidin-4-yl)propionamide) (Other name: 4-  
18       methylfentanyl);
- 19       [~~+68~~] (92) PEPAP (1-(-2-phenethyl)-4-phenyl-4-  
20       acetoxypiperidine);
- 21       [~~+69~~] (93) Phenadoxone;



- 1        [~~70~~] (94) Phenampromide;
- 2        [~~71~~] (95) Phenomorphan;
- 3        [~~72~~] (96) Phenoperidine;
- 4        [~~73~~] (97) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-  
5                N-phenylbenzamide) (Other name: benzoyl fentanyl);
- 6        [~~74~~] (98) Piritramide;
- 7        [~~75~~] (99) Proheptazine;
- 8        [~~76~~] (100) Properidine;
- 9        [~~77~~] (101) Propiram;
- 10       (102) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-  
11                propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
- 12       [~~78~~] (103) Racemoramide;
- 13       (104) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-  
14                yl)-N-phenyltetrahydrofuran-2-carboxamide);
- 15       [~~79~~] (105) Thenylfentanyl (N-[1-(2-thienyl)methyl-4-  
16                piperidyl]-N-phenylpropanamide), its optical isomers,  
17                salts, and salts of isomers;
- 18       [~~80~~] (106) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-  
19                piperidinyl]-propanamide);



1       ~~(81)~~ (107) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-  
2               4-yl)-N-phenylthiophene-2-carboxamide) (Other names:  
3               2-thiofuranyl fentanyl; thiophene fentanyl);

4       ~~(82)~~ (108) Tilidine;

5       ~~(83)~~ (109) Trimeperidine; [and]

6       ~~(84)~~ (110) U-47700 (3,4-dichloro-N-[2-  
7               (dimethylamino)cyclohexyl]-N-methylbenzamide) [-]; and  
8       (111) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
9               phenylpentanamide)."

10       2. By amending subsection (d) to read:

11       "(d) Hallucinogenic substances. Unless specifically  
12       excepted or unless listed in another schedule, any material,  
13       compound, mixture, or preparation that contains any quantity of  
14       the following hallucinogenic substances, including their salts,  
15       isomers, and salts of isomers, whenever the existence of these  
16       salts, isomers, and salts of isomers is possible within the  
17       specific chemical designation:

18       (1) Alpha-ethyltryptamine (AET);

19       (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);

20       (3) 2,5-dimethoxyamphetamine (2,5-DMA);

21       (4) 3,4-methylenedioxy amphetamine;



- 1 (5) 3,4-methylenedioxymethamphetamine (MDMA);
- 2 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
- 3 MDA);
- 4 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
- 5 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 6 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- 7 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- 8 (11) 3,4,5-trimethoxy amphetamine;
- 9 (12) Bufotenine;
- 10 (13) 4-methoxyamphetamine (PMA);
- 11 (14) Diethyltryptamine;
- 12 (15) Dimethyltryptamine;
- 13 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 14 (17) Gamma hydroxybutyrate (GHB) (some other names include
- 15 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
- 16 hydroxybutanoic acid; sodium oxybate; sodium
- 17 oxybutyrate);
- 18 (18) Ibogaine;
- 19 (19) Lysergic acid diethylamide;
- 20 (20) Marijuana;
- 21 (21) Parahexyl;



- 1 (22) Mescaline;
- 2 (23) Peyote;
- 3 (24) N-ethyl-3-piperidyl benzilate;
- 4 (25) N-methyl-3-piperidyl benzilate;
- 5 (26) Psilocybin;
- 6 (27) Psilocyn;
- 7 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
- 8 (29) Ethylamine analog of phencyclidine (PCE);
- 9 (30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
- 10 (31) Thiophene analog of phencyclidine (TCPy; TCP);
- 11 (32) Gamma-butyrolactone, including butyrolactone;
- 12 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 13 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
- 14 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
- 15 hydroxybutyric acid lactone; 3-hydroxybutyric acid
- 16 lactone and 4-hydroxybutanoic acid lactone with
- 17 Chemical Abstract Service number 96-48-0 when any such
- 18 substance is intended for human ingestion;
- 19 (33) 1,4 butanediol, including butanediol; butane-1,4-diol;
- 20 1,4- butylenes glycol; butylene glycol; 1,4-
- 21 dihydroxybutane; 1,4- tetramethylene glycol;



- 1 tetramethylene glycol; tetramethylene 1,4- diol with  
2 Chemical Abstract Service number 110-63-4 when any  
3 such substance is intended for human ingestion;
- 4 (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),  
5 its optical isomers, salts, and salts of isomers;
- 6 (35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its  
7 optical isomers, salts, and salts of isomers;
- 8 (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its  
9 optical isomers, salts, and salts of isomers;
- 10 (37) Alpha-methyltryptamine (AMT);
- 11 (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 12 (39) Salvia divinorum;
- 13 (40) Salvinorin A;
- 14 (41) Divinorin A;
- 15 (42) 5-Methoxy-N,N-Dimethyltryptamine [~~(5-MeO-DIPT)~~] (some  
16 trade or other names: 5-methoxy-3-[2-  
17 (dimethylamino)ethyl]indole; 5-MeO-DMT);
- 18 (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 19 (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
- 20 (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
- 21 (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);



- 1 (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-  
2 2);
- 3 (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine  
4 (2C-T-4);
- 5 (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 6 (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
- 7 (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
- 8 (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
9 methoxybenzyl)ethanamine, its optical, positional, and  
10 geometric isomers, salts, and salts of isomers (Other  
11 names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
- 12 (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
13 methoxybenzyl)ethanamine, its optical, positional, and  
14 geometric isomers, salts, and salts of isomers (Other  
15 names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
- 16 (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
17 methoxybenzyl)ethanamine, its optical, positional, and  
18 geometric isomers, salts, and salts of isomers (Other  
19 names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
- 20 (55) N-ethylhexedrone, its optical, positional, and  
21 geometric isomers, salts, and salts of isomers (Other



- 1 names: [alpha]-ethylaminohexanophenone; 2-  
2 (ethylamino)-1-phenylhexan-1-one);
- 3 (56) Alpha-pyrrolidinohexanophenone, its optical,  
4 positional, and geometric isomers, salts, and salts of  
5 isomers (Other names: [alpha]-PHP; [alpha]-  
6 pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-  
7 yl)hexan-1-one);
- 8 (57) 4-methyl-alpha-ethylaminopentiophenone, its optical,  
9 positional, and geometric isomers, salts, and salts of  
10 isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-  
11 methylphenyl)pentan-1-one);
- 12 (58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical,  
13 positional, and geometric isomers, salts, and salts of  
14 isomers (Other names: MPHP; 4'-methyl-alpha-  
15 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-  
16 (pyrrolidin-1-yl)hexan-1-one);
- 17 (59) Alpha-pyrrolidinoheptaphenone, its optical,  
18 positional, and geometric isomers, salts, and salts of  
19 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-  
20 yl)heptan-1-one);



- 1 (60) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical,  
2 positional, and geometric isomers, salts, and salts of  
3 isomers (Other names: 4-chloro-[alpha]-PVP; 4'-  
4 chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-  
5 chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); ~~[and]~~
- 6 (61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one  
7 (methoxetamine, MXE) [ $\pm$ ];
- 8 (62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-  
9 (ethylamino)butan-1-one) (Other name: bk-EBDB);
- 10 (63) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-  
11 phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol),  
12 including its isomers, esters, ethers, salts, and  
13 salts of isomers, esters and ethers, whenever the  
14 existence of such isomers, esters, ethers and salts is  
15 possible within the specific chemical designation;
- 16 (64) (1-pentyl-1H-indol-3-yl)(2,2,3,3-  
17 tetramethylcyclopropyl)methanone (UR-144);
- 18 (65) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-  
19 tetramethylcyclopropyl)methanone (5-fluoro-UR-144,  
20 XLR11);



- 1        (66) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-  
2        fluorobenzyl)-1H-indazole-3-carboxamide (Other name:  
3        ADB-FUBINACA);
- 4        (67) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
5        carboxamido)-3,3-dimethylbutanoate (Other names:  
6        MDMB-CHMICA, MMB-CHMINACA);
- 7        (68) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-  
8        carboxamido)-3,3-dimethylbutanoate (Other name: MDMB-  
9        FUBINACA); and
- 10       (69) N-ethylpentylone (Other names: ephylone, 1-(1,3-  
11       benzodioxol-5-yl)-2-(ethylamino)pentan-1-one)."
- 12       3. By amending subsection (f) to read:
- 13       "(f) Stimulants. Unless specifically excepted or unless  
14 listed in another schedule, any material, compound, mixture, or  
15 preparation that contains any quantity of the following  
16 substances having a stimulant effect on the central nervous  
17 system, including its salts, isomers, and salts of isomers:
- 18       (1) Amineptine (7-[(10,11-dihydro-5H-  
19       dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid);
- 20       [~~1~~] (2) Aminorex;
- 21       [~~2~~] (3) Cathinone;



- 1        [~~+3~~] (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR);
- 2        (5) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-
- 3        yl)acetate);
- 4        [~~+4~~] (6) Fenethylamine;
- 5        (7) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-
- 6        oxadiazol-3-ium-5-yl) carbamimidate);
- 7        [~~+5~~] (8) Methcathinone;
- 8        (9) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-
- 9        amine);
- 10       [~~+6~~] (10) 4-methylaminorex;
- 11       [~~+7~~] (11) N-ethylamphetamine;
- 12       [~~+8~~] (12) N,N-dimethylamphetamine;
- 13       [~~+9~~] (13) Substituted cathinones, any compound, except
- 14       bupropion or compounds listed under a different
- 15       schedule, structurally derived from 2-aminopropan-1-
- 16       one by substitution at the 1-position with either
- 17       phenyl, naphthyl, or thiophene ring systems, whether
- 18       or not the compound is further modified in any of the
- 19       following ways:
- 20       (A) By substitution in the ring system to any extent
- 21       with alkyl, alkylendioxy, alkoxy, haloalkyl,



1 hydroxyl, or halide substituents, whether or not  
2 further substituted in the ring system by one or  
3 more other univalent substituents;

4 (B) By substitution at the 3-position with an acyclic  
5 alkyl substituent; or

6 (C) By substitution at the 2-amino nitrogen atom with  
7 alkyl, dialkyl, benzyl, or methoxybenzyl groups,  
8 or by inclusion of the 2-amino nitrogen atom in a  
9 cyclic structure.

10 Some other trade names: Mephedrone (2-methylamino-1-p-  
11 tolylpropan-1-one), also known as 4-  
12 methylmethcathinone (4-MMC), methylephedrone or MMCAT;  
13 Methylenedioxypropylvalerone (MDPV, MDPK); methylone or  
14 3,4-methylenedioxypropylmethcathinone; and 1-  
15 (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one,  
16 monohydrochloride, also known as Ethylone, bk-MDEA  
17 hydrochloride, MDEC; 3,4-Methylenedioxy-N-  
18 ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-  
19 methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-  
20 pyrrolidinopropiophenone (4-MePPP); alpha-  
21 pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-



1 benzodioxol-5-yl)-2-(methylamino)butan-1-one  
2 (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-  
3 1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-  
4 (methylamino)pentan-1-one (pentylone, bk-MBDP); 4-  
5 fluoro-N-methylcathinone (4-FMC, flephedrone); 3-  
6 fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-  
7 2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-  
8 pyrrolidinobutiophenone ([alpha]-PBP) and their  
9 optical, positional, and geometric isomers, salts and  
10 salts of isomers, whenever the existence of such  
11 salts, isomers, and salts of isomers is possible; and  
12 [~~(10)~~] (14) 1-(4-methoxyphenyl)-N-methylpropan-2-amine  
13 (Other names: para-methoxymethamphetamine; PMMA)."

14 SECTION 2. Section 329-16, Hawaii Revised Statutes, is  
15 amended by amending subsection (f) to read as follows:

16 "(f) Immediate precursor. Unless specifically excepted or  
17 unless listed in another schedule, any material, compound,  
18 mixture, or preparation [~~which~~] that contains any quantity of  
19 the following substances:

20 (1) Immediate precursor to amphetamine and  
21 methamphetamine:



- 1 (A) Phenylacetone, phenyl-2-propanone (P2P), benzyl  
2 methyl ketone, methyl benzyl ketone;
- 3 (2) Immediate precursors to phencyclidine (PCP):
- 4 (A) 1-phenylcyclohexylamine; or
- 5 (B) 1-piperidinocyclohexanecarbonitrile (PCC); or
- 6 (3) Immediate precursor to [~~Fentanyl~~] fentanyl:
- 7 (A) [~~4-anilino-N-phenethyl-4-piperidine~~] 4-anilino-N-  
8 phenethylpiperidine (ANPP); or
- 9 (B) N-phenyl-N-(piperidin-4-yl)propionamide  
10 (norfentanyl)."

11 SECTION 3. Section 329-20, Hawaii Revised Statutes, is  
12 amended to read as follows:

13 "**§329-20 Schedule IV.** (a) The controlled substances  
14 listed in this section are included in schedule IV.

15 (b) Depressants. Unless specifically excepted or unless  
16 listed in another schedule, any material, compound, mixture, or  
17 preparation that contains any quantity of the following  
18 substances, including its salts, isomers, esters, ethers, and  
19 salts of isomers, whenever the existence of these isomers,  
20 esters, ethers, and salts is possible within the specific  
21 chemical designation, that has a degree of danger or probable



1 danger associated with a depressant effect on the central  
2 nervous system:

- 3 (1) Alprazolam;
- 4 (2) Barbital;
- 5 (3) Brexanolone;
- 6 (4) Bromazepam;
- 7 (5) Butorphanol;
- 8 (6) Camazepam;
- 9 (7) Carisoprodol;
- 10 (8) Chloral betaine;
- 11 (9) Chloral hydrate;
- 12 (10) Chlordiazepoxide;
- 13 (11) Clobazam;
- 14 (12) Clonazepam;
- 15 (13) Clorazepate;
- 16 (14) Clotiazepam;
- 17 (15) Cloxazolam;
- 18 (16) Daridorexant;
- 19 (17) Delorazepam;
- 20 (18) Diazepam;
- 21 (19) Dichloralphenazone (Midrin);



- 1 (20) Estazolam;
- 2 (21) Ethchlorvynol;
- 3 (22) Ethinamate;
- 4 (23) Ethyl loflazepate;
- 5 (24) Fludiazepam;
- 6 (25) Flunitrazepam;
- 7 (26) Flurazepam;
- 8 (27) Fospropofol (Lusedra);
- 9 (28) Halazepam;
- 10 (29) Haloxazolam;
- 11 (30) Ketazolam;
- 12 (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-  
13 yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-  
14 yl)cyclopropane-1-carboxamide);
- 15 (32) Loprazolam;
- 16 (33) Lorazepam;
- 17 (34) Lormetazepam;
- 18 (35) Mebutamate;
- 19 (36) Medazepam;
- 20 (37) Meprobamate;
- 21 (38) Methohexital;



- 1 (39) Methylphenobarbital (mephorbarbital);
- 2 (40) Midazolam;
- 3 (41) Nimetazepam;
- 4 (42) Nitrazepam;
- 5 (43) Nordiazepam;
- 6 (44) Oxazepam;
- 7 (45) Oxazolam;
- 8 (46) Paraldehyde;
- 9 (47) Petrichloral;
- 10 (48) Phenobarbital;
- 11 (49) Pinazepam;
- 12 (50) Prazepam;
- 13 (51) Quazepam;
- 14 (52) Remimazolam;
- 15 (53) Suvorexant;
- 16 (54) Temazepam;
- 17 (55) Tetrazepam;
- 18 (56) Triazolam;
- 19 (57) Zaleplon;
- 20 (58) Zolpidem; [and]
- 21 (59) Zopiclone (Lunesta) [+]; and



1        (60) Zuranolone.

2        [~~(c)~~ ~~Fenfluramine. Any material, compound, mixture, or~~  
3 ~~preparation which contains any quantity of the following~~  
4 ~~substances, including its salts, isomers, and salts of isomers,~~  
5 ~~whenever the existence of such salts, isomers, and salts of~~  
6 ~~isomers is possible: Fenfluramine.~~

7        ~~(d)]~~ (c) Stimulants. Unless specifically excepted or  
8 unless listed in another schedule, any material, compound,  
9 mixture, or preparation [~~which~~] that contains any quantity of  
10 the following substances having a stimulant effect on the  
11 central nervous system, including its salts, isomers, and salts  
12 of such isomers whenever the existence of such salts, isomers,  
13 and salts of isomers is possible within the specific chemical  
14 designation:

- 15        (1) Cathine ((+)-norpseudoephedrine);  
16        (2) Diethylpropion;  
17        (3) Fencamfamin;  
18        (4) Fenproporex;  
19        (5) Lorcaserin;  
20        (6) Mazindol;  
21        (7) Mefenorex;



- 1 (8) Modafinil;
- 2 (9) Pemoline (including organometallic complexes and  
3 chelates thereof);
- 4 (10) Phentermine;
- 5 (11) Pipradrol;
- 6 (12) Serdexmethylphenidate;
- 7 (13) Sibutramine;
- 8 (14) Solriamfetol; and
- 9 (15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).
- 10 [~~e~~] (d) Other substances. Unless specifically excepted  
11 or unless listed in another schedule, any material, compound,  
12 mixture, or preparation [~~which~~] that contains any quantity of  
13 the following substances, including its optical isomers and its  
14 salts, isomers, and salts of isomers:
- 15 (1) Pentazocine; and
- 16 (2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-  
17 2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-  
18 imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic  
19 acid[~~-~~]).
- 20 [~~f~~] (e) The department of law enforcement may except by  
21 rule any compound, mixture, or preparation containing any



1 depressant substance listed in subsection (b) or any stimulant  
2 listed in subsection [~~(d)~~] (c) from the application of all or  
3 any part of this chapter if the compound, mixture, or  
4 preparation contains one or more active medicinal ingredients  
5 not having a depressant or stimulant effect on the central  
6 nervous system, and if the admixtures are included therein in  
7 combinations, quantity, proportion, or concentration that  
8 vitiate the degree of danger or probable danger of the  
9 substances which have a depressant or stimulant effect on the  
10 central nervous system.

11 [~~(g)~~] (f) Narcotic drugs. Unless specifically excepted or  
12 unless listed in another schedule, any material, compound,  
13 mixture, or preparation containing any of the following narcotic  
14 drugs, or their salts calculated as the free anhydrous base or  
15 alkaloid, in limited quantities as set forth below:

16 (1) Not more than one milligram of difenoxin and not less  
17 than twenty-five micrograms of atropine sulfate per  
18 dosage unit;

19 (2) Dextropropoxyphene [~~(alpha-(+)-4-dimethylamino-1,2-~~  
20 ~~diphenyl-3-methyl-2-propionoxybutane);~~] (alpha-(+)-4-



1            dimethylamino-1,2-diphenyl-3-methyl-2-  
2            propionoxybutane); and  
3            (3) 2-[(dimethylamino)methyl]-1-(3-  
4            methoxyphenyl)cyclohexanol, its salts, optical and  
5            geometric isomers and salts of these isomers  
6            (including tramadol)."


7            SECTION 4. Statutory material to be repealed is bracketed  
8 and stricken. New statutory material is underscored.

9            SECTION 5. This Act shall take effect on July 1, 2025.



S.B. NO. 1452  
S.D. 1  
H.D. 2  
C.D. 1

APPROVED this 29th day of May, 2025

A handwritten signature in black ink, appearing to read "Jon L. Green". The signature is written in a cursive style with a large initial "J" and "G".

GOVERNOR OF THE STATE OF HAWAII

**THE SENATE OF THE STATE OF HAWAI'I**

Date: April 30, 2025  
Honolulu, Hawai'i 96813

We hereby certify that the foregoing Bill this day passed Final Reading in the Senate of the Thirty-Third Legislature of the State of Hawai'i, Regular Session of 2025.

  
President of the Senate

  
Clerk of the Senate

SB No. 1452, SD 1, HD 2, CD 1

THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: April 30, 2025  
Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Final Reading in the House of Representatives of the Thirty-Third Legislature of the State of Hawaii, Regular Session of 2025.



Nadine K. Nakamura  
Speaker  
House of Representatives



Brian L. Takeshita  
Chief Clerk  
House of Representatives